Press Releases Archives | Page 32 of 118

Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer

April 1, 2024 By Cade Hildreth, Founder & President Leave a Comment

Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery.

San Diego, CA, April 1, 2024 – Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. This product introduces a reliable solution for researchers in stem cell research and biotechnology, focusing on enhancing cell viability. [Read more…]

Endonovo Therapeutics Files Patent Application for Cell Therapy Created Using Cord Blood and Tissue Derived Cells

March 23, 2024 By Cade Hildreth, Founder & President Leave a Comment

Therapeutic Represents the First Product to Be Created Using the Company’s Cytotronic™ Platform to Expand and Enhance the Therapeutic Properties of Stem Cells

LOS ANGELES, CA– Oct 27, 2015 – Endonovo Therapeutics, Inc. (OTCQB: ENDV), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it has filed a patent application with the United States Patent and Trademark Office (USPTO) on a perivascular cell mixture created using its proprietary Cytotronics™ Platform that would allow for the wide spread use of cord blood in the treatment of malignant and non-malignant hematological disorders. [Read more…]

Fujifilm Investing $200M to Expand CDMO Services and Double Capacity for iPSC-derived Therapeutics

March 23, 2024 By Cade Hildreth, Founder & President Leave a Comment

The investment will double FUJIFILM Cellular Dynamics’s manufacturing capacity for iPSC-derived cell therapies for its partners. New headquarters will include iPSC manufacturing for drug discovery, drug efficacy, and pharmacology applications.

FUJIFILM Diosynth Biotechnologies’ site in Thousand Oaks, CA, will be expanded to support cell therapy CDMO services.

[Read more…]

ExoXpert, a CDMO launched by EXO Biologics to service increasing worldwide demand for exosomes

March 22, 2024 By Cade Hildreth, Founder & President Leave a Comment

Liege, Belgium – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, today announces the worldwide launch of ExoXpert^TM, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers a MSC-based exosome manufacturing platform used in European clinical trials. ExoXpert is a wholly owned subsidiary of EXO Biologics^TM. [Read more…]

Deverra Therapeutics Granted FDA Regenerative Medicine Advanced Therapy and Orphan Drug Designations for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia

March 20, 2024 By Cade Hildreth, Founder & President Leave a Comment

Designations Validate Preliminary Data and Enhances Ability to Offer Dilanubicel to Cancer Patients

SEATTLE, WA, March 19, 2024 – Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT)designation to its lead candidate (dilanubicel) for use in first-line treatment for acute myeloid leukemia (AML). [Read more…]